Table 1.
Recent and ongoing studies for symptomatic treatment for various symptoms of Huntington’s disease. (Only randomized controlled trials were included)
| Indication | Compound | Mechanism of action | Name of the study | Registration ID (last date of update) | Results |
|---|---|---|---|---|---|
| Motor impairment | PF-02545920 | Phosphodiesterase 10A inhibitor | Amaryllis | NCT02197130 (November 2017) |
Completed Safe and well-tolerated [11] |
| PF-02545920 | Phosphodiesterase 10A inhibitor | APACHE | NCT01806896 (December 2017) |
Completed Worsening of chorea [12] |
|
| Pridopidine |
Dopamine stabilizer Sigma 1 receptor agonist |
PRIDE-HD | NCT02006472 (March 2019) |
Completed Negative for efficacy [13] |
|
| SOM3355 | Vesicular monoamine transporter 2 inhibitor | – | NCT03575676 (September 2019) |
Completed Results not in public domain |
|
| Triheptanoin | Anaplerotic therapy | TRIHEP3 | NCT02453061 (July 2019) |
Ongoing Not recruiting |
|
| Chorea | Risperidone | Dopamine antagonist | – | NCT04201834 (April 2020) | Not yet recruiting |
| Valbenazine | VMAT2 inhibitor | Kinect-HD | NCT04102579 (May 2020) |
Ongoing Recruiting |
|
| AFQ056 | Metabotropic glutamate receptor 5 antagonist | – | NCT01019473 (September 2011) |
Completed Safe and well-tolerated Negative for efficacy [14] |
|
| Pallidal stimulation (DBS) | Neuromodulation | HD-DBS | NCT02535884 (August 2019) |
Ongoing Recruiting |
|
| Pallidal stimulation (DBS) | Neuromodulation | – | NCT04244513 (January 2020) | Not yet recruiting | |
| PINS Stimulator System | Neuromodulation | – | NCT02263430 (October 2016) | Recruitment status unknown | |
| Irritability | SRX246 | Vasopressin 1a receptor antagonist | STAIR |
(October 2019) |
Completed No results in public domain |
| Dextromethorphan/quinidine | Morphinan/class I antiarrhythmic agent | – | NCT03854019 (April 2019) |
Ongoing Recruiting |
|
| Apathy | Bupropion | Norepinephrine/dopamine reuptake inhibitor | Action-HD | NCT01914965 (September 2014) |
Completed Negative for efficacy [15] |
| Cognition | PBT2 | Inhibition of metal-induced aggregation of mHTT | – | NCT01590888 (July 2016) |
Completed Safe and well-tolerated [16] |
| (2)-Epigallocatechin-3-gallate | Polyphenol | ETON | NCT01357681 (June 2015) |
Completed No results in public domain |
|
| Neflamapimod | p38α MAPK inhibitor | – | NCT03980938 (July 2019) |
Ongoing Recruiting |
|
| SAGE-718 | NMDA receptor modulator | NCT03787758 (November 2019) |
Completed Safe and well-tolerated (n = 10 HD patients) Phase II study announced [17] |
||
| Functional ability | Varenicline | Nicotinic agonist | VCAS-HD | ACTRN12616001611415 (November 2016) | Ongoing |
| Cannabinoid mixture | Reduce inflammation and oxidative stress | – | NCT01502046 (February 2013) |
Completed Safe and well-tolerated Negative for efficacy [18] |